glp 1 agonist news Upcoming wave of hormone-based therapies set to change field of diabetes, obesity care Three new studies reveal surprising
Description
Is there an oral GLP-1 agonist
2025;55(1):e14330
Riediger, T., Rauch, M
Zheng RH, Bai XJ, Zhang WW, Wang J, Bai F, Yan CP, James EA, Bose HS, Wang NP, Zhao ZQ
We discuss the significance of new research into neuroendocrine dysfunction, disrupted steroidogenesis, and changes in adipocyte biology, and the potential implications for the diagnosis and management of polycystic ovary syndrome
The recent position statement by the ADA advocating the use of both SGLT2i and GLP-1 RAs is encouraging, indicating that CKD in T2DM is under the spotlight
